PUBLISHER: The Business Research Company | PRODUCT CODE: 1682175
PUBLISHER: The Business Research Company | PRODUCT CODE: 1682175
Contrast-enhanced ultrasound (CEUS) is a medical imaging technique that employs contrast agents or microbubbles to improve the visibility and clarity of ultrasound images. Its application extends to imaging blood perfusion in organs and measuring blood flow rates in the heart and other bodily organs.
The primary components of contrast-enhanced ultrasound are equipment and contrast agents. Equipment encompasses the physical tools, machinery, devices, or instruments designed to perform specific tasks, operations, or functions. This category includes ultrasound machines and associated devices utilized to generate real-time images using contrast agents. These technologies involve both non-targeted and targeted approaches, catering to the needs of hospitals, clinics, and various other applications.
The contrast enhanced ultrasound market research report is one of a series of new reports from The Business Research Company that provides contrast enhanced ultrasound market statistics, including the contrast enhanced ultrasound industry global market size, regional shares, competitors with contrast enhanced ultrasound market share, detailed contrast enhanced ultrasound market segments, market trends and opportunities, and any further data you may need to thrive in the contrast enhanced ultrasound industry. This contrast enhanced ultrasound market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The contrast enhanced ultrasound market size has grown strongly in recent years. It will grow from $2.05 billion in 2024 to $2.16 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to diagnostic accuracy and sensitivity, non-invasiveness and safety, rising incidence of liver diseases, global increase in aging population, growing preference for non-radiation techniques.
The contrast enhanced ultrasound market size is expected to see strong growth in the next few years. It will grow to $2.69 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to rise in cardiovascular diseases, increasing applications in pediatric imaging, expanding role in gastrointestinal imaging, growing focus on precision medicine, integration with artificial intelligence. Major trends in the forecast period include continued technological innovations, advancements in ultrasound technology, expanding applications in oncology, integration with multimodal imaging, real-time quantitative assessment, pediatric applications.
The rising prevalence of chronic diseases is expected to significantly drive the growth of the contrast-enhanced ultrasound market. Chronic diseases are long-term medical conditions that require ongoing management and care, and contrast-enhanced ultrasound (CEUS) provides real-time, detailed imaging crucial for diagnosing and monitoring these conditions. For instance, in September 2023, the World Health Organization reported that approximately 41 million deaths annually, accounting for 74% of all global deaths, are attributed to non-communicable diseases (NCDs), which include many chronic diseases like liver cirrhosis and vascular disorders linked to hypertension. CEUS is particularly valuable in these contexts, as it enhances the visibility of blood flow and tissue perfusion, aiding in the accurate assessment and management of chronic diseases. As the incidence of these conditions continues to rise, the demand for advanced imaging techniques such as contrast-enhanced ultrasound is likely to increase, further propelling market growth.
The increasing number of ambulatory surgical centers is anticipated to contribute to the growth of the contrast-enhanced ultrasound market. Ambulatory Surgery Centers (ASCs) specialize in offering outpatient surgical procedures. Contrast-enhanced ultrasound (CEUS) finds application in these centers to provide real-time image guidance during minimally invasive procedures. In 2022, according to VMG Health, the total number of certified ambulatory surgical centers increased from 5,906 in 2021 to 6,028 centers in 2022. Therefore, the expanding presence of ambulatory surgical centers is expected to drive the contrast-enhanced ultrasound market's growth.
Major companies in the contrast-enhanced ultrasound market are focusing on developing advanced technologies, such as super-resolution contrast-enhanced ultrasound (CEUS) technology, to enhance spatial resolution. The integration of advanced technologies in contrast-enhanced ultrasound improves diagnostic capabilities, providing healthcare professionals with more detailed and accurate information about tissue and organ anatomy, function, and perfusion. In September 2023, Philips launched the Philips Microvascular Imaging Super Resolution Contrast-Enhanced Ultrasound (CEUS), utilizing advanced signal processing algorithms to enhance spatial resolution. This technology provides high-resolution images for diagnosing and treating various diseases, including cancer, liver disease, and vascular diseases.
In July 2024, GE HealthCare Technologies Inc., a US-based medical technology company, announced its acquisition of Intelligent Ultrasound Group PLC for an undisclosed amount. This strategic acquisition aims to integrate Intelligent Ultrasound's advanced solutions into GE HealthCare's existing ultrasound portfolio, enhancing both the efficiency and intelligence of their ultrasound offerings. The integration of these AI-driven technologies is expected to significantly improve the accuracy and usability of ultrasound systems, addressing the increasing demand for smarter imaging solutions within the healthcare industry. Intelligent Ultrasound Group PLC, based in the UK, specializes in innovative ultrasound systems, particularly focusing on applications related to contrast-enhanced ultrasound. This acquisition aligns with GE HealthCare's commitment to advancing imaging technologies and improving patient care through enhanced diagnostic capabilities.
Major companies operating in the contrast enhanced ultrasound market report are General Electric Company, Bayer AG, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Koninklijke Philips N.V., Daiichi Sankyo Company Limited, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., J.B. Chemicals and Pharmaceuticals Ltd., Canon Medical Systems, Lantheus Medical Imaging Inc., Guerbet, Bracco Diagnostic Inc., Esaote S.p.A., Trivitron Healthcare Pvt. Ltd., BK Medical Holding Company Inc., Hitachi Healthcare, Chison Medical Technology Co. Ltd., SANOCHEMIA Pharmazeutika GmbH, SuperSonic Imagine SA, FUJIFILM Visualsonics Inc., Leriva Pharma SA, Samsung Healthcare, Jodas Expoim Pvt Ltd., nanoPET Pharma GmbH, Alpinion Medical Systems, Acusphere Inc., ContextVision AB, Teratech Corporation, Solstice Pharmaceuticals B.V.
North America was the largest region in the contrast-enhanced ultrasound market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the contrast enhanced ultrasound market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the contrast-enhanced ultrasound market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The contrast-enhanced ultrasound market consists of revenues earned by entities by providing services such as diagnostic imaging services, treatment planning services, and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The contrast-enhanced ultrasound market also includes sales of transducers, injectors, guidance tools, and imaging software that are used in providing comprehensive contrast-enhanced ultrasound. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Contrast Enhanced Ultrasound Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on contrast enhanced ultrasound market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for contrast enhanced ultrasound ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The contrast enhanced ultrasound market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.